The 76 references in paper D. Duplancic ., M. Cesarik ., N. Poljak K., M. Radman ., V. Kovacic ., J. Radic ., V. Rogosic ., Д. Дупланчич ., М. Цезарич ., Н. Поляк К., М. Радман ., В. Ковачич ., Ж. Радич ., В. Рогозич . (2014) “Влияние селективного активатора рецептора витамина D парикальцитола на сердечно-сосудистую систему и кардиоренальную протекцию // The influence of selective vitamin D receptor activator paricalcitol on cardiovascular system and cardiorenal protection” / spz:neicon:nefr:y:2014:i:2:p:25-32

1
Webb RA. Who, what, where and when – influences on cutaneous vitamin D synthesis. Prog Biophys Mol Biol 2006;92:17–25
(check this in PDF content)
2
Dusso AS, Brown AJ, Slatopolsky E. Vitamin D. Am J Physiol Renal Physiol 2005;289:8–28
(check this in PDF content)
3
Grant WB, Holick MF. Benefits and requirements of vitamin D for optimal health: A review. Altern Med Rev 2005;10:94–111
(check this in PDF content)
4
Lappe JM, Travers-Gustafson D, Davies KM, et al. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr 2007;85:1586–1591
(check this in PDF content)
5
Gouni-Berthold I, Krone W, Berthold HK. Vitamin D and cardiovascular disease. Curr Vasc Pharmacol 2009;7:414–422
(check this in PDF content)
6
Parker J, Hashmi O, Dutton D, et al. Levels of vitamin D and cardiometabolic disorders: systematic review and meta-analysis. Maturitas 2010;65:225–236
(check this in PDF content)
7
Scragg R, Sowers M, Bell C. Serum 25-hydroxyvitamin D, ethnicity, and blood pressure in the Third National Health and Nutrition Examination Survey. Am J Hypertens 2007;20:713–719
(check this in PDF content)
8
Freedman BI, Wagenknecht LE, Hairston KG, et al. Vitamin D, adiposity, and calcified atherosclerotic plaque in African-Americans. J Clin Endocrinol Metab 2010;95:1076–1083
(check this in PDF content)
9
DeLuca HF. Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr 2004;80(Suppl 6):S1689–S1696
(check this in PDF content)
10
Mitsuhashi T, Morris RC Jr, Ives HE. 1,25-dihydroxyvitamin D3 modulates growth of vascular smooth muscle cells. J Clin Invest 1991;87:1889–1895
(check this in PDF content)
11
Michos ED, Melamed ML. Vitamin D and cardiovascular disease risk. Curr Opin Clin Nutr Metab Care 2008;11:7–12
(check this in PDF content)
12
Panichi V, De Pietro S, Andreini B, et al. Calcitriol modulates in vivo and in vitro cytokine production: a role for intracellular calcium. Kidney Int 1998;54:1463–1469
(check this in PDF content)
13
Bellows CG, Reimers SM, Heersche JN. Expression of mRNAs for type-I collagen, bone sialoprotein, osteocalcin, and osteopontin at different stages of osteoblastic differentiation and their regulation by 1,25 dihydroxyvitamin D3. Cell Tissue Res 1999;297:249–259
(check this in PDF content)
14
Drissi H, Pouliot A, Koolloos C, et al. 1,25-(OH)2-vitamin D3 suppresses the bone-related Runx2/Cbfa1 gene promoter. Exp Cell Res 2002;274:323–333
(check this in PDF content)
15
Aihara K, Azuma H, Akaike M, et al. Disruption of nuclear vitamin D receptor gene causes enhanced thrombogenicity in mice. J Biol Chem 2004;279:35798–35802
(check this in PDF content)
16
Simpson RU, Hershey SH, Nibbelink KA. Characterization of heart size and blood pressure in the vitamin D receptor knockout mouse. J Steroid Biochem Mol Biol 2007;103:521–524
(check this in PDF content)
17
Meems LM, van der Harst P, van Gilst WH, de Boer RA. Vitamin D biology in heart failure: molecular mechanisms and systematic review. Curr Drug Targets 2011;12:29–41
(check this in PDF content)
18
Talmor Y, Golan E, Benchetrit S, et al. Calcitriol blunts the deleterious impact of advanced glycation end products on endothelial cells. Am J Physiol Renal Physiol 2008;294:1059–1064
(check this in PDF content)
19
Hsia J, Heiss G, Ren H, et al. Calcium/vitamin D supplementation and cardiovascular events. Circulation 2007;115:846–854
(check this in PDF content)
20
Zittermann A, Frisch S, Berthold HK, et al. Vitamin D supplementation enhances the beneficial effects of weight loss on cardiovascular disease risk markers. Am J Clin Nutr 2009; 89:1321–1327
(check this in PDF content)
21
Elamin MB, Abu Elnour NO, Elamin KB, et al. Vitamin D and cardiovascular outcomes: a systematic review and meta-analysis. J Clin Endocrinol Metab 2011;96:1931–1942
(check this in PDF content)
22
Autier P, Gandini S. Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials. Arch Intern Med 2007;167(16):1730–1737
(check this in PDF content)
23
Dobnig H, Pilz S, Scharnagl H, Renner W, et al. Independent association of low serum 25-hydroxyvitamin d and 1,25-dihydroxyvitamin d levels with all-cause and cardiovascular mortality. Arch Intern Med 2008;168:1340–1349
(check this in PDF content)
24
Inaguma D, Nagaya H, Hara K, et al. Relationship between serum 1,25-dihydroxyvitamin D and mortality in patients with predialysis chronic kidney disease. Clin Exp Nephrol 2008;12:126–131
(check this in PDF content)
25
Baker LR, Abrams L, Roe CJ, et al. 1,25(OH)2D3 administration in moderate renal failure: a prospective double-blind trial. Kidney Int 1989; 35:661–669
(check this in PDF content)
26
Moe SM, Drüeke TB, Block GA, et al. KDIGO clinical practice guidelines for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl 2009;113:S1–S130
(check this in PDF content)
27
Moe S, Drüeke T, Cunningham J, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 69:1945–1953
(check this in PDF content)
28
Watson KE, Abrolat ML, Malone LL, et al. Active serum vitamin D levels are inversely correlated with coronary calcification. Circulation 1997;96:1755–1760
(check this in PDF content)
29
Teng M, Wolf M, Ofsthun MN, et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005;16:1115–1125
(check this in PDF content)
30
Bianchi ML, Colantonio G, Campanini F, et al. Calcitriol and calcium carbonate therapy in early chronic renal failure. Nephrol Dial Transplant 1994;9:1595–1599
(check this in PDF content)
31
Yildiz A, Memisoglu E, Oflaz H, et al. Atherosclerosis and vascular calcification are independent predictors of left ventricular hypertrophy in chronic haemodialysis patients. Nephrol Dial Transplant 2005;20:760–767
(check this in PDF content)
32
London GM. Cardiovascular calcifications in uremic patients: clinical impact on cardiovascular function. J Am Soc Nephrol 2003;9 Suppl 4: S305–S309
(check this in PDF content)
33
Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32:S112–S119
(check this in PDF content)
34
No authors listed]. VI. Causes of death in ESRD. Am J Kidney Dis 1999;34(2 Suppl 1):S87–S94
(check this in PDF content)
35
No authors listed]. V. Patient mortality and survival in ESRD. Am J Kidney Dis 1999;34:(2 Suppl 1):S74–S86
(check this in PDF content)
36
Goodman WG, Coburn JW. The use of 1,25-dihydroxyvitamin D3 in early renal failure. Annu Rev Med 1992;43:227–237
(check this in PDF content)
37
Demer LL, Tintut Y. Vascular calcification: pathobiology of multifaceted disease. Circulation 2008;117:2938–2948
(check this in PDF content)
38
Bas A, Lopez I, Perez J, Rodriguez M, Aguilera-Tejero E. Reversibility of calcitriol-induced medial artery calcification in rats with intact renal function. J Bone Miner Res 2006;21:484–490
(check this in PDF content)
39
Stubbs JR, Liu S, Tang W, et al. Role of hyperphosphatemia and 1,25-dihydroxyvitamin D in vascular calcification and mortality in fibroblastic growth factor 23 null mice. J Am Soc Nephrol 2007;18:2116–2124
(check this in PDF content)
40
Cozzolino M, Brancaccio D, Gallieni M, Slatopolsky E. Pathogenesis of vascular calcification in chronic kidney disease. Kidney Int 2005;68:429–436
(check this in PDF content)
41
Brown AJ, Finch J, Takahashi F, Slatopolsky E. Calcemic activity of 19-Nor-1,25(OH)(2)D(2) decreases with duration of treatment. J Am Soc Nephrol 2000;11:2088–2094
(check this in PDF content)
42
Mizobuchi M, Ogata H, Koiwa F, Kinugasa E, Akizawa T. Vitamin D and vascular calcification in chronic kidney disease. Bone 2009; 45 Suppl 1:S26–S29
(check this in PDF content)
43
Andress D. Nonclassical aspects of differential vitamin D receptor activation: implications for survival in patients with chronic kidney disease. Drugs 2007;67:1999–2012
(check this in PDF content)
44
Cheng J, Zhang W, Zhang X, Li X, Chen J. Efficacy and safety of paricalcitol therapy for chronic kidney disease: a metaanalysis. Clin J Am Soc Nephrol 2012;7:391–400
(check this in PDF content)
45
Sprague SM, Llach F, Amdahl M, Taccetta C, Batlle D. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 2003;63:1483–1490
(check this in PDF content)
46
Brown JA, Finch J, Slatopolsky E. Differential effects of 19-nor-1,25-dihydroxyvitamin D2 and 1,25-dihydroxyvitamin D3 on intestinal calcium and phosphate transport. J Lab Clin Med 2002;139:279–284
(check this in PDF content)
47
Nakane M, Ma J, Rose AE, et al. Differential effects of vitamin D analogs on calcium transport. J Steroid Biochem Mol Biol 2007;103:84–89
(check this in PDF content)
48
Sprague SM, Lerma E, McCormmick D, et al. Suppression of parathyroid hormone secretion in hemodialysis patients: comparison of paricalcitol with calcitriol. Am J Kidney Dis 2001;38:S51–S56
(check this in PDF content)
49
Takahashi F, Finch JL, Denda M, Dusso AS, Brown AJ, Slatopolsky E. A new analog of 1,25-(OH)2D3, 19-NOR-1,25(OH)2D2, suppresses serum PTH and parathyroid gland growth in uremic rats without elevation of intestinal vitamin D receptor content. Am J Kidney Dis 1997;30:105–112
(check this in PDF content)
50
Rodriguez M, Martinez-Moreno JM, Rodríguez-Ortiz ME, Muñoz-Castañeda JR, Almaden Y. Vitamin D and vascular calcification in chronic kidney disease. Kidney Blood Press Res 2011;34:261–268
(check this in PDF content)
51
Li X, Speer MY, Yang H, Bergen J, Giachelli CM. Vitamin D receptor activators induce an anticalcific paracrine program in macrophages: requirement of osteopontin. Arterioscler Thromb Vasc Biol 2010;30: 321–326
(check this in PDF content)
52
Sanchez-Niño MD, Bozic M, Córdoba-Lanús E, et al. Beyond proteinuria: VDR activation reduces renal inflammation in experimental diabetic nephropathy. Am J Physiol Renal Physiol 2012;302:647–657
(check this in PDF content)
53
Resnick LM, Müller FB, Laragh JH. Calcium-regulating hormones in essential hypertension. Relation to plasma renin activity and sodium metabolism. Ann Intern Med 1986;105:649–654
(check this in PDF content)
54
Freundlich M, Quiroz Y, Zhang Z, et al. Suppression of renin-angiotensin gene expression in the kidney by paricalcitol. Kidney Int 2008;74:1394–1402
(check this in PDF content)
55
Park JW, Bae EH, Kim IJ, et al. Renoprotective effects of paricalcitol on gentamicin-induced kidney injury in rats. Am J Physiol Renal Physiol 2010;298:301–313
(check this in PDF content)
56
Sochorová K, Budinský V, Rozková D, et al. Paricalcitol (19-nor-1, 25-dihydroxyvitamin D2) and calcitriol (1,25-dihydroxyvitamin D3) exert potent immunomodulatory effects on dendritic cells and inhibit induction of antigen-specific T cells. Clin Immunol. 2009;133:69–77
(check this in PDF content)
57
Ari E, Kedrah AE, Alahdab Y, et al. Antioxidant and renoprotective effects of paricalcitol on experimental contrast-induced nephropathy model. Br J Radiol 2012;85:1038–1043
(check this in PDF content)
58
Meems LM, Cannon MV, Mahmud H, et al. The vitamin D receptor activator paricalcitol prevents fibrosis and diastolic dysfunction in a murine model of pressure overload. J Steroid Biochem Mol Biol 2012;132:282–289
(check this in PDF content)
59
Husain K, Ferder L, Mizobuchi M, Finch J, Slatopolsky E. Combination therapy with paricalcitol and enalapril ameliorates cardiac oxidative injury in uremic rats. Am J Nephrol 2009;29:465–472
(check this in PDF content)
60
Park JW, Cho JW, Joo SY, et al. Paricalcitol prevents cisplatin-induced renal injury by suppressing apoptosis and proliferation. Eur J Pharmacol 2012;683:301–309
(check this in PDF content)
61
Mizobuchi M, Morrissey J, Finch JL, et al. Combination therapy with an angiotensin-converting enzyme inhibitor and a vitamin D analog suppresses the progression of renal insufficiency in uremic rats. J Am Soc Nephrol 2007;18:1796–1806
(check this in PDF content)
62
Husain K, Suarez E, Isidro A, Ferder L. Effects of paricalcitol and enalapril on atherosclerotic injury in mouse aortas. Am J Nephrol 2010;32:296–304
(check this in PDF content)
63
Kong J, Kim GH, Wei M, et al. Therapeutic effects of vitamin D analogs on cardiac hypertrophy in spontaneously hypertensive rats. Am J Pathol 2010;177:622–631
(check this in PDF content)
64
Mizobuchi M, Nakamura H, Tokumoto M, et al. Myocardial effects of VDR activators in renal failure. J Steroid Biochem Mol Biol 2010;121: 188–192
(check this in PDF content)
65
Fraga C, Blanco M, Vigo E, et al. Autogenesis of the vitamin D receptor in the rat heart. Histochem Cell Biol 2002;117:547–550
(check this in PDF content)
66
Wu-Wong JR, Noonan W, Nakane M, et al. Vitamin d receptor activa-tion mitigates the impact of uremia on endothelial function in the 5/6 nephrectomized rats. Int J Endocrinol Epub February 10, 2010
(check this in PDF content)
67
Mizobuchi M, Finch JL, Martin DR, Slatopolsky E. Differential effects of vitamin D receptor activators on vascular calcification in uremic rats. Kidney Int 2007;72:709–715
(check this in PDF content)
68
Cardús A, Panizo S, Parisi E, Fernandez E, Valdivielso JM. Differential effects of vitamin D analogs on vascular calcification. J Bone Miner Res 2007;22:860–866
(check this in PDF content)
69
Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. Engl J Med 31, 2003;349:446–456
(check this in PDF content)
70
Tentori F, Hunt WC, Stidley CA, et al. Mortality risk among hemo-dialysis patients receiving different vitamin D analogs. Kidney Int 2006;70:1858–1865
(check this in PDF content)
71
Cozzolino M, Brancaccio D, Cannella G, et al. VDRA therapy is associated with improved survival in dialysis patients with serum intact PTH < = 150 pg/mL: results of the Italian FARO Survey. Nephrol Dial Transplant 2012;27(9):3588–3594
(check this in PDF content)
72
He W, Kang YS, Dai C, Liu Y. Blockade of Wnt/? – catenin signaling by paricalcitol ameliorates proteinuria and kidney injury. J Am Soc Nephrol 2011;22:90–103
(check this in PDF content)
73
Aperis G, Paliouras C, Zervos A, Arvanitis A, Alivanis P. The role of paricalcitol on proteinuria. J Ren Care 2011;37:80–84
(check this in PDF content)
74
Agarwal R, Acharya M, Tian J, et al. Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int 2005; 68:2823–2828
(check this in PDF content)
75
Zeeuw D, Agarwal R, Amdahl M, et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 2010;376:1543–1551
(check this in PDF content)
76
Thadhani R, Appelbaum E, Pritchett Y. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA 2012;307:674–684 Статья переведена на русский язык и публикуется
(check this in PDF content)